

13 February 2025

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain.

The Directors of the Company accept responsibility for the content of this announcement.

**Physiomics plc
("Physiomics" or the "Company")**

**Physiomics completes Placing to fund growth opportunities
Launch of WRAP Retail Offer**

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has completed a placing, conditional on Admission, of, in aggregate, £430,000 (gross) from the issue of 86,000,000 new ordinary shares of £0.004 each (the "**Placing Shares**") at an issue price of £0.005 per Placing Share (the "**Placing Price**") through the Company's broker, Hybridan LLP (the "**Placing**"). The Placing Price represents a discount of approximately 37.5 per cent. to the mid-market closing price of an ordinary share on 12 February 2025 (being the latest practicable date prior to this announcement).

The Company will also shortly be launching a retail offering to the Company's existing shareholders to raise up to an additional £70,000 by way of the issue of a further 14,000,000 new ordinary shares of £0.004 each (the "**WRAP Retail Offer Shares**") at the Placing Price.

In order to further develop its business and accelerate growth, the Company is raising funds to carry out the following activities and for general working capital.

- **Mathematical Modelling Consulting Service**
 - Recruitment of further technical team members to accelerate the conversion of the pipeline and support service delivery;
 - Investment in Business Development and Marketing to build and strengthen the pipeline, expand into new therapeutic areas, further develop its data science offering and refresh messaging; and
 - Explore strategic options to accelerate the growth of modelling services.
- **Biostatistics Consulting Service**
 - Organic growth of the service through Business Development and Marketing to acquire clients; and
 - Explore strategic options to accelerate the growth of biostatistics services.
- **Personalised Medicine Tool Development**
 - Explore a deeper relationship with DoseMe to develop models to be implemented on their platform; and
 - Implementation of the Company's current personalised dosing tool on the DoseMeRx Platform enabling it to be made available to clinicians across the US.
- **General Working Capital**

The Company has made significant progress since its last placing in July 2024, including:

- Dr Mark Davies joined the Company as the Head of Quantitative Pharmacology and Data Science;
- Launch of biostatistics services and expansion of core consulting to data science and bioinformatics;
- New contract awards from existing clients including Cancer Research UK, and another contract with Numab Therapeutics AG;
- Publication of peer-reviewed papers with a former large pharma client Astellas Pharma Inc. and with client Merck KGaA;
- Predict-ONC trial received regulatory and ethical approval; and
- Dr Peter Sargent (appointed CEO in January 2024) implemented a restructuring of operating staff to better position the business for growth.

Retail Offering:

The Company is pleased to announce that a retail offer to existing shareholders will be shortly launched via the Winterford Retail Access Platform ("WRAP"), to raise up to an additional £70,000 (the "WRAP Retail Offer"), through the issue of up to 14,000,000 WRAP Retail Offer Shares, at the Placing Price.

The proceeds of the WRAP Retail Offer will be utilised in the same way as the proceeds of the Placing. For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing. Completion of the WRAP Retail Offer is conditional, *inter alia*, upon the completion of the Placing, but completion of the Placing is not conditional on the completion of the WRAP Retail Offer. The WRAP Retail Offer is conditional on the WRAP Retail Offer Shares being admitted to trading.

The Company values its shareholder base and believes that it is appropriate to provide its existing retail shareholders in the United Kingdom the opportunity to participate in its fundraising.

The WRAP Retail Offer is expected to close at **11.00 a.m. on 17 February 2025**.

Admission and Total Voting Rights

Application will be made for the Placing Shares to be issued pursuant to the Placing and the WRAP Retail Offer Shares to be issued pursuant to the WRAP Retail Offer and each to be admitted to trading on AIM and dealing is expected to commence on or around 18 February 2025 ("Admission"). A further announcement regarding the enlarged issued share capital for the purposes of the Financial Services Authority's Disclosure Guidance and Transparency Rules will be made following completion of the Placing and the WRAP Retail Offer.

Dr Peter Sargent, CEO, commented:

"We want to thank our loyal shareholders for their continued support. Over the last 12-months, Physiomics has achieved a record year for the total value of contract wins and is tracking in line with expectations for the full year ending 30 June 2025. The quality and impact of the Company's solutions can be evidenced in the two recent publications, with partners Astellas Pharma Inc and Merck KGaA, but also the success of Numab Therapeutics' NM26 asset - an early clinical programme supported by Physiomics prior to being acquired by J&J for US 1.2 billion. These recent case studies will become invaluable tools in building our pipeline further and winning new business. With this latest round of funding, investment is being made in key growth initiatives across the business as we remain in active discussions with a variety of clients on several further contracts."

Enquiries:

Physiomics plc
Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & Cancer Research UK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOESFIFAEIIEFE